Dubai Longevity Authority Strategy: Why Clinical Governance and Evidence-Based Marketing Will Determine Its Credibility
Dubai’s approval of the Dubai Longevity Authority’s strategy and operating budget moves the emirate’s longevity agenda from institutional design towards implementation. Following the Authority’s inaugural board meeting, the announced priorities include regulatory development, supervised pilots and market activation. The size of the operating budget has not been disclosed in the reporting reviewed for this article. The separately reported ambition to contribute more than AED 35 billion to Dubai’s economy over a decade is an economic target, not the Authority’s budget.
The opportunity extends well beyond premium wellness clinics. It encompasses preventive services, advanced therapeutics, medical devices, diagnostics, digital monitoring, research and the infrastructure needed to evaluate them. For providers and investors, this creates a consequential question: which offerings can demonstrate meaningful benefit, appropriate safety and honest communication when assessed as healthcare rather than as lifestyle products?
Longevity is particularly vulnerable to a gap between scientific possibility and commercial certainty. A change in a laboratory marker, an attractive mechanism of action or a small early study can be presented as though it establishes longer life or better health. Those are different claims. A regulated market needs ways to distinguish established prevention, promising interventions under evaluation and services whose claimed outcomes are unsupported.
The Dubai Longevity Authority strategy should therefore be understood as both an innovation programme and a test of clinical governance. This article examines the legal framework, the requirements for robust services and devices, the responsibilities of healthcare marketing, and the due diligence that boards and clinical leaders should undertake before launch.
Dubai Longevity Authority Strategy Moves From Establishment to Supervised Implementation
Law No. 17 of 2026 established the Dubai Longevity Authority with objectives that include safe and effective preventive and therapeutic activity, research, scientific trials, ethical integrity and protection of individuals. Its remit covers the development and provision of services, therapies and products related to longevity. The law empowers the Authority to classify activities, set standards, regulate pilots, issue establishment permits, inspect providers and promote evidence-based practice in coordination with existing authorities.
The September announcement describes a phased approach, including a controlled minimum viable product programme in which selected innovators can test solutions under supervision while regulatory capabilities develop.
That is a significant design choice. A pilot is a controlled means of learning, with entry criteria, defined outcomes and oversight. It does not itself establish that a therapy works or confer general approval for commercial claims.
The legal architecture also requires attention to overlapping responsibilities. The Authority’s permit framework applies to longevity activity across Dubai, including free zones, while Law No. 17 preserves the functions of other competent entities. The Dubai Health Authority retains responsibilities relating to health professionals and services in coordination with the new Authority. Founders should map the specific establishment, professional, product, research and advertising approvals relevant to each offering rather than assume that one permission covers an entire business model. Detailed implementation requirements will depend on subsequent rules and the classification of the activity.
The commercial significance is equally clear. A credible regulatory pathway may attract researchers, manufacturers, clinicians and capital. It may also expose weaknesses in ventures that rely on broad anti-ageing language without a defined patient population, reproducible protocol or defensible outcome. The companies best prepared for this environment will treat oversight as part of product development from the outset.
Clinical Robustness Begins With the Claim Being Made
“Longevity” can describe several different propositions. A service may help patients manage established risks for cardiovascular disease and diabetes. A wearable may improve detection or adherence. A therapeutic intervention may change a biological marker. A provider may go further and claim to delay ageing, reduce future disease or extend life. Each step requires its own evidence and its own assessment of benefit against burden and harm.
The first discipline is to state the intended use precisely: for whom, for what clinical problem, by which method, compared with what alternative, and with which measurable outcome? An intervention supported by results in a narrowly selected population cannot automatically be marketed to healthy adults. A device that measures a signal accurately does not necessarily improve decisions or outcomes. A biomarker that changes after treatment does not necessarily show that patients function better, remain independent longer or live longer.
Clinical governance translates those distinctions into operations. A provider needs eligibility and exclusion criteria, an assessment of baseline risk, a written treatment protocol, appropriately trained staff, an authorised setting and a reliable process for complications. Consent must explain the plausible benefit, material uncertainty, alternatives and foreseeable harms. Follow-up should capture adverse events and outcomes that matter to patients, not simply repeat whichever marker generated the sale.
Independent review is particularly valuable when the evidence is preliminary and the intervention is profitable.
The clinical director should have authority to pause a service, revise its criteria or reject a marketing claim. Boards should receive regular reports on incidents, complaints, outcomes, deviations from protocol and emerging evidence. Governance is substantive only when it can change commercial decisions.
For devices and digital tools, the same approach extends through the product lifecycle. Founders should distinguish analytical performance from clinical validity and clinical utility. They should assess data quality across the population in which the device will be used, define who interprets an abnormal finding, establish escalation thresholds and test how the tool fits into a real care pathway. Procurement should include maintenance, cybersecurity, privacy, training and post-market monitoring, as appropriate to the device and its regulatory category.
Plasmapheresis Illustrates Why Promising Science Requires Careful Boundaries
The death of Greek singer Giorgos Mazonakis on 9 September has prompted understandable concern and a continuing investigation in Greece. Reports say he suffered a cardiac arrest after attending an Athens medical practice for a planned plasmapheresis procedure. Accounts have differed on whether the procedure had begun. At the time of publishing this article, the cause of death had not been established by the initial forensic examination, and investigators have examined the circumstances, timing and licensing of the practice. His death should be discussed with respect for his family and without implying that the procedure caused it or that any individual is responsible before the investigation concludes.
The case does, however, focus attention on questions that every provider must answer before offering an invasive elective intervention.
What is the indication?
What evidence supports its use for this patient?
Is the facility authorised and equipped for the procedure?
Are the team’s competencies current?
What assessment precedes treatment, and how would the team recognise, resuscitate and transfer a patient who deteriorates?
Therapeutic plasma exchange has established roles for particular diseases, and the American Society for Apheresis publishes evidence-based categories for its clinical indications. That established medical use should not be conflated with a claim that routine plasma exchange extends healthy life in otherwise healthy people.
There is legitimate research into ageing-related biomarkers. A small randomised study involving 42 people reported changes in several biological-age measures after therapeutic plasma exchange, while its authors described the findings as hypothesis-generating and called for larger validation. Another randomised study of a different plasmapheresis protocol in healthy adults found no significant epigenetic rejuvenation and did not establish conclusive benefit. The protocols and populations differ, so neither result should be treated as a universal verdict. Neither establishes improved healthspan or survival.
That distinction is the point of due diligence.
A credible provider can explain the precise protocol, its evidence, uncertainty and risks without borrowing certainty from another indication or another study. If a proposed service is still investigational, it should be evaluated through an appropriate research or supervised pilot pathway, with the relevant ethics and regulatory approvals, rather than sold using an unqualified rejuvenation promise.
Evidence-Based Marketing Is a Clinical Responsibility
The way a healthcare facility markets longevity services can influence whether a person seeks an unnecessary test, delays established care or accepts an invasive procedure. Advertising is consequently part of clinical risk management. A claim that a treatment “reverses ageing” or a device “prevents disease” should be interrogated with the same care as the protocol behind it.
Dubai’s existing framework already places obligations on licensed providers and professionals.
The DHA has circulated standards for medical advertisement content on social media and expects material to be ethical and reliable for patient decision-making. Its published standards require substantiation of treatment-outcome claims and communication of associated risks; they warn against exaggerated or absolute promises, unsupported products and undisclosed material interests.
Medical directors have explicit responsibility for the accuracy and balance of facility content. Dubai’s health-professions resolution also addresses authorisation for health promotion and approval of facility service advertising. The precise approval route should be checked against the current rules and the regulator with jurisdiction over the advertiser and product.
For a longevity programme, responsible communication starts with naming the service and its intended purpose in ordinary clinical language. A provider should say whether an intervention is established care, an adjunctive service or investigational; identify the population studied; describe the benefit actually measured; and state material risks and limitations with comparable prominence. If evidence rests on a surrogate biomarker, the advertisement should not convert that result into a claim of longer life.
Device marketing requires an additional distinction between what a product records and what it can establish clinically. A sensor may reliably estimate a physiological variable without diagnosing disease. An algorithm may stratify risk without proving that acting on its output improves outcomes. Testimonials, dramatic imagery and a clinician’s title cannot replace validation in the intended setting.
Providers also need a controlled publishing process. Clinical, regulatory and communications leads should review claims against a versioned evidence file before release. The file should identify the underlying studies, approved intended use, licence status, qualifying language and review date. The same standards should apply to a clinician’s social account, an investor presentation, an influencer collaboration, a website and a sales script. A promotion can mislead through omission even when every sentence is literally true.
The Board-Level Due Diligence Test for Longevity Ventures
Boards and investors should ask for more than a scientific deck and a legal opinion. They should request a service-by-service matrix showing the intended use, evidence grade, relevant approvals, responsible clinician, site requirements, patient selection, consent process and emergency response. For each device, they should ask what is validated, in which population, by whom and against what comparator.
The financial model should be examined alongside the clinical model. Subscription revenue, bundled testing and treatment upsells can create incentives to overtest, overtreat or imply certainty that evidence does not support. Compensation, referral arrangements and manufacturer relationships need transparent management. A clinical governance committee should be able to recommend discontinuation even when a service is popular.
Pilots should be designed to resolve defined uncertainties. Their protocols should specify primary endpoints, adverse-event capture, data protection, inclusion criteria, comparator or baseline, and conditions for stopping or scaling. Where human-subject research is involved, the appropriate ethical and regulatory route is essential. Commercial uptake and customer satisfaction are informative business metrics, but they cannot stand in for safety or clinical effectiveness.
The new Authority’s emphasis on data and regulated experimentation creates a further obligation. Genomic results, longitudinal biomarkers and wearable data may reveal sensitive information or produce findings of uncertain significance. Consent for clinical care, secondary research and commercial data use should be distinguished. Patients should know who can access their information, for what purpose, how a finding is reviewed and what happens when permissions change. Law No. 17 envisages a unified protocol with the DHA that includes protection of individuals’ information and procedures for longevity communications. [3]
Strategic Assessment: Trust Must Be Designed Into the Market
Approval of the Dubai Longevity Authority strategy and operating budget signals that Dubai intends to organise longevity as a regulated healthcare and innovation sector. The immediate opportunity is to build services, therapeutics and devices that can survive scrutiny from patients, clinicians, regulators and institutional partners. The immediate risk is allowing the language of longevity to run ahead of clinical proof.
The strongest ventures will separate established prevention from experimental intervention, match every public claim to its evidence, obtain the permissions appropriate to the activity, and give clinical leaders real authority over safety and quality. The reported Greek case is a reminder to perform these checks before a patient enters the treatment room, while the investigation must be allowed to determine its own facts.
Pnyx Hill Healthcare Advisors can support founders, providers and investors through a structured review of clinical propositions, service and device pathways, evidence and claim substantiation, governance arrangements, pilot design and GCC market entry. Its role is most useful before scale: identifying what can be offered now, what requires further validation and what should not yet be marketed as a clinical benefit. For Dubai’s longevity sector, that discipline is a foundation for both patient trust and durable investment.
References
Government of Dubai Media Office. Hamdan bin Mohammed approves Dubai Longevity Authority’s strategy and budget following inaugural board meeting. 27 September 2026.
Gulf News. Sheikh Hamdan approves Dubai Longevity strategy targeting Dh35 billion economic boost. 27 September 2026.
Government of Dubai, Supreme Legislation Committee. Law No. (17) of 2026 Establishing the Dubai Longevity Authority. 6 June 2026.
Euronews. Giorgos Mazonakis: Arrests and new evidence amid probe into Greek star’s death. 10 September 2026.
eKathimerini. Mazonakis cause of death remains undetermined after autopsy. 11 September 2026.
eKathimerini. Prosecutors order fresh probe into clinic where Mazonakis died. 16 September 2026
American Society for Apheresis. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue. Journal of Clinical Apheresis, 2026. DOI: 10.1002/jca.70141.
Fuentealba et al. Multi-Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single-Blinded Randomized Placebo-Controlled Therapeutic Plasma Exchange. 2025.
Borsky et al. Human clinical trial of plasmapheresis effects on biomarkers of aging (efficacy and safety trial). Scientific Reports, 2025.
Dubai Health Authority. Standards for Medical Advertisement Content on Social Media — Circular CIR-2026-00000144. 17 August 2026.
Dubai Health Authority. Standards for Medical Advertisement Content on Social Media, Version 1.1. Code: DHA/HRS/HPSD/ST-21. Issued 3 August 2022; effective 3 October 2022.
Government of Dubai, Supreme Legislation Committee. Executive Council Resolution No. (49) of 2024 Regulating the Practice of Health Professions and Health Activities in the Emirate of Dubai.
Disclaimer: This article is provided for general information only and does not constitute legal, regulatory or medical advice, an official interpretation of applicable requirements, or an endorsement of any treatment or provider. It reflects information available at the date of publication. Readers should verify current requirements with the relevant authorities and seek advice from appropriately qualified legal and healthcare professionals before making decisions.